Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed metastatic melanoma to the lung for which no known standard therapy exists
• At least 1 unidimensionally measurable lesion
• HLA-A2 positive (part A patients only)
• Previously treated CNS metastases allowed provided there is no evidence of disease progression within the past 3 months
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• ECOG 0-2
• Life expectancy:
• At least 12 weeks
• Hematopoietic:
• Absolute neutrophil count at least 1,000/mm\^3
• Platelet count at least 75,000/mm\^3
• Hemoglobin at least 8.0 g/dL
• Hepatic:
• Bilirubin no greater than 2 times upper limit of normal (ULN)
• AST no greater than 3 times ULN
• Renal:
• Creatinine no greater than 2.5 times ULN
• Cardiovascular:
• No New York Heart Association class III or IV heart disease
• Pulmonary:
• No pulmonary disease requiring concurrent active therapy (e.g., supplemental oxygen or bronchodilator)
• FEV\_1 at least 65% of predicted and at least 1.5 L
• Immunologic:
• No known immunodeficiency state
• No known autoimmune disease
• No uncontrolled infection
• Other:
• No active psychotic disorder requiring pharmacotherapy
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• More than 2 weeks since prior biologic therapy
• More than 2 weeks since prior immunotherapy
• More than 4 weeks since prior filgrastim (G-CSF) or sargramostim (GM-CSF)
• No other concurrent biologic therapy or immunotherapy
• No concurrent G-CSF
• No concurrent GM-CSF other than study drug
• Chemotherapy:
• More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
• No concurrent chemotherapy
• Endocrine therapy:
• More than 2 weeks since prior corticosteroids
• No concurrent glucocorticosteroids
• Radiotherapy:
• More than 2 weeks since prior radiotherapy
• No concurrent radiotherapy
• Surgery:
• Not specified
• Other:
• More than 7 days since prior parenteral antibiotics
• No concurrent parenteral antibiotics
• No concurrent immunosuppressive agents